Spurred by recent progress in materials chemistry and drug delivery, stimuli-responsive devices that deliver a drug in spatial-, temporal- and dosage-controlled fashions have become possible. Implementation of such devices requires the use of biocompatible materials that are susceptible to a specific physical incitement or that, in response to a specific stimulus, undergo a protonation, a hydrolytic cleavage or a (supra)molecular conformational change. In this Review, we discuss recent advances in the design of nanoscale stimuli-responsive systems that are able to control drug biodistribution in response to specific stimuli, either exogenous (variations in temperature, magnetic field, ultrasound intensity, light or electric pulses) or endogenous (changes in pH, enzyme concentration or redox gradients).

Stimuli-responsive nanocarriers for drug delivery

Polymeric materials have been used in a range of pharmaceutical and biotechnology products for more than 40 years. These materials have evolved from their earlier use as biodegradable products such as resorbable sutures, orthopaedic implants, macroscale and microscale drug delivery systems such as microparticles and wafers used as controlled drug release depots, to multifunctional nanoparticles (NPs) capable of targeting, and controlled release of therapeutic and diagnostic agents. These newer generations of targeted and controlled release polymeric NPs are now engineered to navigate the complex in vivo environment, and incorporate functionalities for achieving target specificity, control of drug concentration and exposure kinetics at the tissue, cell, and subcellular levels. Indeed this optimization of drug pharmacology as aided by careful design of multifunctional NPs can lead to improved drug safety and efficacy, and may be complimentary to drug enhancements that are traditionally achieved by medicinal chemistry. In this regard, polymeric NPs have the potential to result in a highly differentiated new class of therapeutics, distinct from the original active drugs used in their composition, and distinct from first generation NPs that largely facilitated drug formulation. A greater flexibility in the design of drug molecules themselves may also be facilitated following their incorporation into NPs, as drug properties (solubility, metabolism, plasma binding, biodistribution, target tissue accumulation) will no longer be constrained to the same extent by drug chemical composition, but also become in-part the function of the physicochemical properties of the NP. The combination of optimally designed drugs with optimally engineered polymeric NPs opens up the possibility of improved clinical outcomes that may not be achievable with the administration of drugs in their conventional form. In this critical review, we aim to provide insights into the design and development of targeted polymeric NPs and to highlight the challenges associated with the engineering of this novel class of therapeutics, including considerations of NP design optimization, development and biophysicochemical properties. Additionally, we highlight some recent examples from the literature, which demonstrate current trends and novel concepts in both the design and utility of targeted polymeric NPs (444 references).

/pdf/targeted-polymeric-therapeutic-nanoparticles-design-pj01q1y8xh.pdf

Targeted polymeric therapeutic nanoparticles: design, development and clinical translation

Chemistries that Facilitate Nanotechnology Kim E. Sapsford,† W. Russ Algar, Lorenzo Berti, Kelly Boeneman Gemmill,‡ Brendan J. Casey,† Eunkeu Oh, Michael H. Stewart, and Igor L. Medintz*,‡ †Division of Biology, Department of Chemistry and Materials Science, Office of Science and Engineering Laboratories, U.S. Food and Drug Administration, Silver Spring, Maryland 20993, United States ‡Center for Bio/Molecular Science and Engineering Code 6900 and Division of Optical Sciences Code 5611, U.S. Naval Research Laboratory, Washington, D.C. 20375, United States College of Science, George Mason University, 4400 University Drive, Fairfax, Virginia 22030, United States Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Sacramento, California 95817, United States Sotera Defense Solutions, Crofton, Maryland 21114, United States

Functionalizing nanoparticles with biological molecules: developing chemistries that facilitate nanotechnology.

In this Review, we aim to provide an updated summary of the research related to hollow micro- and nanostructures, covering both their synthesis and their applications. After a brief introduction to the definition and classification of the hollow micro-/nanostructures, we discuss various synthetic strategies that can be grouped into three major categories, including hard templating, soft templating, and self-templating synthesis. For both hard and soft templating strategies, we focus on how different types of templates are generated and then used for creating hollow structures. At the end of each section, the structural and morphological control over the product is discussed. For the self-templating strategy, we survey a number of unconventional synthetic methods, such as surface-protected etching, Ostwald ripening, the Kirkendall effect, and galvanic replacement. We then discuss the unique properties and niche applications of the hollow structures in diverse fields, including micro-/nanocontainers and rea...

Synthesis, Properties, and Applications of Hollow Micro-/Nanostructures

Bhushan S. Pattni,† Vladimir V. Chupin,‡ and Vladimir P. Torchilin*,†,§,∥ †Department of Pharmaceutical Sciences, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, Massachusetts 02115, United States ‡Laboratory for Advanced Studies of Membrane Proteins, Moscow Institute of Physics and Technology, Dolgoprudny 141700, Russia Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia

New Developments in Liposomal Drug Delivery.

Background: Targeted liposomes can be broadly defined as liposomes that are engineered to interact with a particular population of cells with the objective of delivering a payload or increasing their retention within the targeted cell population by means of a chemical interaction with cell-surface molecules or other tissue-specific ligands. Objective: The authors review recent advances in the field with an emphasis on pre-clinical studies and place them in the context of historical developments. Methods: The review focuses on immunoliposomes (antibody-mediated targeting) as these constructs are presently the most prevalent. Conclusion: The field has advanced in tandem with advances in liposome design and antibody and protein engineering. Targeted liposomes have been used in diagnosis to deliver magnetic resonance contrast agents and radionuclides for magnetic resonance and nuclear medicine imaging, respectively. They have been used in gene therapy to deliver a variety of gene expression modifiers, includi...

Antibody-targeted liposomes in cancer therapy and imaging

Disseminated, metastatic cancer is frequently incurable. Targeted α-particle emitters hold great promise as therapeutic agents for disseminated disease. 225Ac is a radionuclide generator that has a 10-d half-life and results in α-emitting daughter elements (221Fr, 217At, 213Bi) that lead to the emission of a total of 4 α-particles. The aim of this study was to develop approaches for stable and controlled targeting of 225Ac to sites of disseminated tumor metastases. Liposomes with encapsulated 225Ac were developed to retain the potentially toxic daughters at the tumor site. Methods:225Ac was passively entrapped in liposomes. To experimentally test the retention of actinium and its daughters by the liposomes, the γ-emissions of 213Bi were measured in liposome fractions, which were separated from the parent liposome population and the free radionuclides, at different times. Under equilibrium conditions the decay rate of 213Bi was used to determine the concentration of 225Ac. Measurements of the kinetics of 213Bi activity were performed to estimate the entrapment of 213Bi, the last α-emitting daughter in the decay chain. Results: Stable pegylated phosphatidylcholine-cholesterol liposomes of different sizes and charge were prepared. Multiple (more than 2) 225Ac atoms were successfully entrapped per liposome. 225Ac retention by zwitterionic liposomes was more than 88% over 30 d. Retention by cationic liposomes was lower. A theoretical calculation showed that for satisfactory 213Bi retention (>50%), liposomes of relatively large sizes (>650 nm in diameter) are required. 213Bi retention was experimentally verified to be liposome-size dependent. For large liposomes, the measured 213Bi retention was lower than theoretically predicted (less than 10%). Conclusion: This work supports the hypothesis that it may be possible to develop 225Ac-based therapies by delivering multiple 225Ac atoms in liposomes. Improvements in the retention of 225Ac daughters will likely be necessary to fulfill this potential. Because of the size of the liposomal structures required to contain the daughters, the approach is ideally suited for locoregional therapy (e.g., intraperitoneal, intrahepatic artery, or intrathecal).

https://jnm.snmjournals.org/content/jnumed/45/2/253.full.pdf

Engineered Liposomes for Potential α-Particle Therapy of Metastatic Cancer

This review describes strategies for the delivery of therapeutic radionuclides to tumor sites. Therapeutic approaches are summarized in terms of tumor location in the body, and tumor morphology. These determine the radionuclides of choice for suggested targeting ligands, and the type of delivery carriers. This review is not exhaustive in examples of radionuclide carriers for targeted cancer therapy. Our purpose is two-fold: to give an integrated picture of the general strategies and molecular constructs currently explored for the delivery of therapeutic radionuclides, and to identify challenges that need to be addressed. Internal radiotherapies for targeting of cancer are at a very exciting and creative stage. It is expected that the current emphasis on multidisciplinary approaches for exploring such therapeutic directions should enable internal radiotherapy to reach its full potential.

/pdf/radionuclide-carriers-for-targeting-of-cancer-6wbrmjk2k2.pdf

Radionuclide carriers for targeting of cancer

This study evaluates targeted liposomes loaded with the α-particle generator 225Ac to selectively kill prostate-specific membrane antigen (PSMA)–expressing cells with the aim to assess their potential for targeted antivascular radiotherapy. Methods: In this study, PEGylated liposomes were loaded with 225Ac and labeled with the mouse antihuman PSMA J591 antibody or with the A10 PSMA aptamer. The targeting selectivity, extent of internalization, and killing efficacy of liposomes were evaluated on monolayers of prostate cancer cells intrinsically expressing PSMA (human LNCaP and rat Mat-Lu cells) and on monolayers of HUVEC induced to express PSMA (induced HUVEC). Results: The loading efficiency of 225Ac into preformed liposomes ranged from 58.0% ± 4.6% to 85.6% ± 11.7% of introduced radioactivity. The conjugation reactions resulted in approximately 17 ± 2 J591 antibodies and 9 ± 2 A10 aptamers per liposome. The average size of liposomes, 107 ± 2 nm in diameter, was not affected by conjugation or loading. LNCaP cells exhibit 2:1:0.5 relative PSMA expression, compared with MatLu and induced HUVEC, respectively, based on flow cytometry detecting association of the J591 antibody. J591-labeled liposomes display higher levels of total specific binding to all cell lines than A10 aptamer-labeled liposomes. Specific cell association of targeted liposomes increases with incubation time. Cytotoxicity studies demonstrate that radiolabeled J591-labeled liposomes are most cytotoxic, with median lethal dose values, after 24 h of incubation, equal to 1.96 (5.3 × 10−5), 2.92 × 102 (7.9 × 10−3), and 2.33 × 101 Bq/mL (6.3 × 10−4 μCi/mL) for LNCaP, Mat-Lu, and induced HUVEC, respectively, which are comparable to the values for the radiolabeled J591 antibody. For A10 aptamer–labeled liposomes, the corresponding values are 3.70 × 101 (1.0 × 10−3), 1.85 × 103 (5.0 × 10−2), and 4.07 × 103 Bq/mL (1.1 × 10−1 μCi/mL), respectively. Conclusion: Our studies demonstrate that anti-PSMA–targeted liposomes loaded with 225Ac selectively bind, become internalized, and kill PSMA-expressing cells including endothelial cells induced to express PSMA. These findings—combined with the unique ability of liposomes to be easily tuned, in terms of size and surface modification, for optimizing biodistributions—suggest the potential of PSMA-targeting liposomes encapsulating α-particle emitters for selective antivascular α radiotherapy.

https://jnm.snmjournals.org/content/jnumed/55/1/107.full.pdf

Stavroula Sofou

Papers

Antibody-targeted liposomes in cancer therapy and imaging

Engineered Liposomes for Potential α-Particle Therapy of Metastatic Cancer

Radionuclide carriers for targeting of cancer

Anti–Prostate-Specific Membrane Antigen Liposomes Loaded with 225Ac for Potential Targeted Antivascular α-Particle Therapy of Cancer

Enhanced Retention of the α-Particle-Emitting Daughters of Actinium-225 by Liposome Carriers